CAMBRIDGE, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company
developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and
Chief Executive Officer, will present a corporate overview at the 2018 JMP Securities Life Sciences Conference, being held in New
York City on June 20-21, 2018.
JMP Securities Life Sciences Conference – Leap Presentation Details:
Date: Wednesday, June 20, 2018
Time: 11:30 A.M.
The presentation will be webcast live and may be accessed on the Investors page of the company’s website at www.investors.leaptx.com, where a replay of the event will also be available for a limited
time.
About Leap Therapeutics
Leap Therapeutics (NASDAQ:LPTX) is developing targeted and immuno-oncology therapeutics. Leap’s most advanced clinical candidate,
DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical
trials in patients with esophagogastric cancer, biliary tract cancer, and gynecologic cancers, with an emerging focus on patients
with defined mutations of the Wnt pathway and in combinations with immune checkpoint inhibitors. Leap’s second clinical candidate,
TRX518, is a novel, humanized GITR agonist monoclonal antibody designed to enhance the immune system’s anti-tumor response that is
in two advanced solid tumor studies. For more information about Leap Therapeutics, visit http://www.leaptx.com or our public filings with the SEC that are available via EDGAR at
http://www.sec.gov or via http://www.investors.leaptx.com/.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and
uncertainties. These statements include statements relating to Leap’s expectations with respect to the development and advancement
of DKN-01, TRX518, and other programs, including the initiation, timing and design of future studies, enrollment in future studies,
business development, and other future expectations, plans and prospects. Detailed information regarding factors that may cause
actual results to differ materially will be included in Leap Therapeutics’ periodic filings with the Securities and Exchange
Commission (the "SEC"), including Leap Therapeutics’ Form 10-K that Leap filed with the SEC on February 23, 2018. Any forward
looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking
statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of
unanticipated events.
CONTACT:
Douglas E. Onsi
Chief Financial Officer
Leap Therapeutics, Inc.
donsi@leaptx.com
617-714-0360
Argot Partners
Investor Relations
Susan Kim or Heather Savelle
212-600-1902
susan@argotpartners.com
heather@argotpartners.com